Disease · MONDO_0021107

narcolepsy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. narcolepsy. Diseases, record MONDO_0021107. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021107

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: narcolepsy; Open Targets
Open Targets ID: MONDO_0021107; Open Targets
Other names: narcolepsy with or without cataplexy, paroxysmal sleep; Open Targets
Disease Ontology: DOID:8986; Disease Ontology
MeSH: D009290; MeSH
NCI Thesaurus: C84489; NCI Thesaurus
Orphanet: ORPHA:619284; Orphanet
Highest stage of its drugs: Approval, for 5 of its 17 drugs, from EMA Human Drugs, PMDA and TTD; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MODAFINIL	CHEMBL1373	Small molecule	Approval	PMDA and TTD	12	10	10	Drugs and targets
SODIUM OXYBATE	CHEMBL1200682	Small molecule	Approval	EMA Human Drugs and TTD	11	9	9	Drugs and targets
PITOLISANT	CHEMBL462605	Small molecule	Approval	EMA Human Drugs	8	7	7	Drugs and targets
SOLRIAMFETOL	CHEMBL4297620	Small molecule	Approval	EMA Human Drugs	7	5	5	Drugs and targets
DEXTROAMPHETAMINE	CHEMBL612	Small molecule	Approval	TTD	1	0	0	Drugs and targets
ARMODAFINIL	CHEMBL1201192	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
REBOXETINE	CHEMBL14370	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
SUVN-G3031	CHEMBL4297328	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
FLECAINIDE	CHEMBL652	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
MAZINDOL	CHEMBL781	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets12

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HRH3	Histamine H3 receptor	4	Histamine H3 receptor antagonist; Histamine H3 receptor inverse agonist	Approval	https://conductscience.org/library/genes/11255	Drugs and targets
SLC6A3	Monoamine transporter	4	Dopamine transporter inhibitor; Dopamine transporter releasing agent; Monoamine transporter inhibitor	Approval	https://conductscience.org/library/genes/6531	Drugs and targets
SLC6A2	Monoamine transporter	3	Monoamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent	Approval	https://conductscience.org/library/genes/6530	Drugs and targets
GABBR1	GABA-B receptor	2	GABA-B receptor agonist	Approval	https://conductscience.org/library/genes/2550	Drugs and targets
GABBR2	GABA-B receptor	2	GABA-B receptor agonist	Approval	https://conductscience.org/library/genes/9568	Drugs and targets
ADORA1	Adenosine receptor	1	Adenosine receptor antagonist	Phase 1/2	https://conductscience.org/library/genes/134	Drugs and targets
ADORA2A	Adenosine receptor	1	Adenosine receptor antagonist	Phase 1/2	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine receptor	1	Adenosine receptor antagonist	Phase 1/2	https://conductscience.org/library/genes/136	Drugs and targets
ADORA3	Adenosine receptor	1	Adenosine receptor antagonist	Phase 1/2	https://conductscience.org/library/genes/140	Drugs and targets
SCN5A	Sodium channel protein type 5 subunit alpha	1	Sodium channel protein type V alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6331	Drugs and targets

1 to 10 of 12

See all 12 targets

Trials46

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00228553	Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness	Phase 3	743	2010-03-31	Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Chronic Shift Work Sleep Disorder	ARMODAFINIL	Its record names the disease	ClinicalTrials.gov
NCT02348632	"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"	Phase 3	645	2019-06-25	Narcolepsy, Obstructive Sleep Apnea	SOLRIAMFETOL	Its record names the disease	ClinicalTrials.gov
NCT00078312	Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder	Phase 3	328	2010-02-22	Narcolepsy, Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Shift-Work Sleep Disorder	ARMODAFINIL	Its record names the disease	ClinicalTrials.gov
NCT00228566	Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome	Phase 3	247	2010-06-25	Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)	ARMODAFINIL	Its record names the disease	ClinicalTrials.gov
NCT02348593	"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"	Phase 3	239	2019-07-23	Narcolepsy	SOLRIAMFETOL	Its record names the disease	ClinicalTrials.gov
NCT00066170	Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy	Phase 3	231	2011-11-30	Narcolepsy	MODAFINIL, SODIUM OXYBATE	Its record names the disease	ClinicalTrials.gov
NCT02720744	Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy	Phase 3	212	2022-03-22	Excessive Daytime Sleepiness, Cataplexy, Narcolepsy	SODIUM OXYBATE	Its record names the disease	ClinicalTrials.gov
NCT03030599	A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy	Phase 3	201	2020-11-12	Narcolepsy With Cataplexy	SODIUM OXYBATE	Its record names the disease	ClinicalTrials.gov
NCT00078377	Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy	Phase 3	196	2010-01-21	Narcolepsy	ARMODAFINIL	Its record names the disease	ClinicalTrials.gov
NCT04072380	A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy	Phase 2	190	2025-01-13	Narcolepsy	SUVN-G3031	Its record names the disease	ClinicalTrials.gov

1 to 10 of 46

See all 46 trials

Comparisons in its trials26

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
JZP-110 vs Placebo: deaths from any cause	1 of 643	0 of 142	785	NCT02348632	Trial comparisons
JZP-110 vs Placebo: serious adverse events	27 of 643	0 of 142	785	NCT02348632	Trial comparisons
JZP-258 vs Placebo: deaths from any cause	0 of 201	0 of 65	266	NCT03030599	Trial comparisons
JZP-258 vs Placebo: serious adverse events	5 of 201	2 of 65	266	NCT03030599	Trial comparisons
FT218 9g Group vs Placebo 9g Group: deaths from any cause	0 of 77	0 of 80	157	NCT02720744	Trial comparisons
FT218 9g Group vs Placebo 9g Group: serious adverse events	1 of 77	0 of 80	157	NCT02720744	Trial comparisons
Safety Population vs Randomized Placebo: deaths from any cause	0 of 104	0 of 32	136	NCT02221869	Trial comparisons
Safety Population vs Randomized Placebo: serious adverse events	2 of 104	0 of 32	136	NCT02221869	Trial comparisons
JZP-258 vs Placebo: Number of Participants With Worsening Patient Global Impression of Change (PGIc) for Narcolepsy Overall	3 of 69	29 of 65	134	NCT03030599	Trial comparisons
JZP-258 vs Placebo: Number of Participants With Worsening Clinical Global Impression of Change (CGIc) for Narcolepsy Overall	4 of 68	39 of 65	133	NCT03030599	Trial comparisons

1 to 10 of 26

See all 26 comparisons in its trials

Papers from its trials42

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39504585	RESULT	1	PubMed
21206549	RESULT	1	PubMed
16895262	RESULT	1	PubMed
42163487	DERIVED	1	PubMed
40851446	DERIVED	1	PubMed
40111739	DERIVED	1	PubMed
40111738	DERIVED	1	PubMed
39321628	DERIVED	1	PubMed
39263597	DERIVED	1	PubMed
39153911	DERIVED	1	PubMed

1 to 10 of 42

See all 42 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021107

GET https://conductscience.org/api/diseases/v1/MONDO_0021107/trials?page=2

API reference For AI assistants